# Telehealth Semaglutide and Tirzepatide Program: 12.3% at 24 Weeks | This GLP A 180-person single-arm study of telemedicine semaglutide and tirzepatide prescribing found 12.3% weight loss at 24 weeks | what the intervention included beyond the prescription. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/telehealth-glp1-program-trial Updated: 2026-10-26 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Telehealth Semaglutide and Tirzepatide Program: 12.3% at 24 Weeks A single-arm telehealth program produced 12.3% weight loss in 24 weeks. Alongside the prescription, it supplied a behavioral program, a connected scale and a blood pressure cuff. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 What the 12.3% result was produced by · the drug · the part sellers ship · behavioral program · connected scale · blood pressure cuff · Single arm, 180 participants, 24 weeks **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A 24-week single-arm study followed 180 people prescribed semaglutide or tirzepatide through a telehealth program. - Weight loss was 7.2% at twelve weeks and 12.3% at twenty-four, p<0.0001. - Blood pressure fell from a mean of 131.0/83.8 to 120.0/78.2. - The intervention was not just a prescription: it included a behavioral program, a connected scale and a blood pressure cuff. - There was no control group, and side effects were compared informally against published trials rather than measured against a comparator. Nearly all the evidence for these drugs comes from trials run through clinics. Almost all the buying happens through websites. The gap between those two sentences is where most of this market lives, so a study of telemedicine prescribing is worth reading carefully — and this one rewards the care, because the thing it studied is not quite the thing being sold. ## What happened One hundred and eighty people recruited from a telehealth medical obesity program received semaglutide or tirzepatide along with a virtual behavioral program designed for long-acting obesity medications, a Bluetooth scale and a blood pressure cuff. [\[1\]](https://thisglp.com/research/telehealth-glp1-program-trial#ref-1) Participants averaged 44 years old and 102.8 kg; 91% were women and 81% were white. Weight, blood pressure, eating habits, diet quality, activity and side effects were assessed at baseline, twelve weeks and twenty-four. Weight fell 7.2% at twelve weeks and 12.3% at twenty-four, both at p<0.0001. Mean blood pressure went from 131.0/83.8 to 122.5/78.7 at twelve weeks and 120.0/78.2 at twenty-four. Eating habits, diet quality and activity all improved significantly. Those are good numbers, comparable to what the trials report, obtained without anybody walking into a clinic. Four things were delivered. Sellers ship one. The intervention included a structured behavioral program, hardware for weighing yourself, and a cuff for tracking blood pressure between visits. A result produced by that package cannot be attributed to the prescription inside it. Almost nothing on this roster comes with a behavioral program, and [the disclosure scorecard](https://thisglp.com/tools/what-sellers-publish) shows how few sellers describe any ongoing support at all. ## What the design cannot tell you There was no control group. Everyone received everything, so there is no way to know what the behavioral program added over the drug alone, or what the drug added over the program alone, or what either added over the kind of person who signs up for a structured twenty-four-week study and owns a connected scale. The analysis also carried the last observation forward for people who stopped contributing data. On a weight endpoint that is a generous convention — somebody who dropped out at week thirteen keeps their week-twelve loss on the books at week twenty-four, and a person who left because it was not working is recorded at their best point rather than their last. Real-world persistence is poor enough that this matters, as [the gap between trials and practice](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care) keeps showing. ## The claim not to repeat The paper reports that side effects were markedly lower than in previously reported trials. That comparison is the weakest thing in it, and it is the line most likely to be quoted by somebody selling this delivery model. Randomized trials capture adverse events systematically, with scheduled questioning and predefined categories, from participants who did not choose their treatment. An unblinded single-arm program collects what people volunteer between virtual visits. Lower numbers from the second method are what you would expect whether or not fewer things happened. Nothing here establishes that telehealth delivery is gentler, and the study did not set out to. ## What it does support Something real and narrower. A well-built remote program, with structured behavioral support and simple home monitoring, produced trial-comparable weight loss and meaningful blood pressure improvement over six months in people who stayed with it. That is a useful thing to know, and it is an argument for the package rather than for the convenience. It also sets a standard a buyer can hold a seller to. If a site is selling remote weight management, does it provide anything beyond a prescription and a refill schedule? Most here do not say, which is its own kind of answer — [the pattern runs across every clinical question](https://thisglp.com/research/what-glp1-sellers-do-not-publish) this market touches, right down to [which states they will ship to](https://thisglp.com/research/who-publishes-the-states-they-serve). Published service descriptions provide a separate shopping comparison, not a replication of this study. [Lavender Sky Health](https://thisglp.com/reviews/lavender-sky-health) offers phone, video or e-consult appointments on its [website](https://lavenderskyhealth.com/). Ask which contact format and follow-up schedule your own plan includes; the availability of telehealth alone does not establish the support used in this trial. ## Frequently asked Does telehealth work as well as a clinic? This study cannot answer that, because it had no comparison group. It showed that one well-supported remote program produced 12.3% weight loss at 24 weeks in the people who stayed in it. Why does the behavioral program matter? Because it was part of what produced the result, along with a connected scale and a blood pressure cuff. A prescription on its own was not what was studied. Were side effects really lower? Unknown. The paper compares its self-reported tallies against published randomized trials, which capture adverse events systematically. The two methods do not produce comparable numbers. Who was in it? 180 people averaging 44 years and 102.8 kg, of whom 91% were women and 81% were white, recruited from an existing telehealth obesity program. ## Sources 1. \[1\] Heinberg LJ, et al. (2026). Effectiveness of Telemedicine Prescribing and a Long-Acting Obesity Medication Behavioral Program: A 24-Week Single-Arm Study Obesity. [PMID 41253738](https://pubmed.ncbi.nlm.nih.gov/41253738/) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)